53
1
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T6396 |
(R)-(-)-Gossypol acetic acid
(-)-Gossypol acetic acid,AT-101 (acetic acid),(R)-Gossypol acetic acid,AT101醋酸,AT101,AT101 acetate |
BCL; Autophagy | Apoptosis; Autophagy |
(R)-(-)-Gossypol acetic acid (AT101 acetate) 是天然产物 Gossypol 的左旋异构体,与 Bcl-2、Bcl-xL 和 Mcl-1 结合,Ki 为 0.32 μM、0.48 μM 和 0.18 μM。 | |||
T5170 |
KHS101 hydrochloride
盐酸KHS101 |
FGFR; Microtubule Associated | Angiogenesis; Cytoskeletal Signaling; Tyrosine Kinase/Adaptors |
KHS101 hydrochloride 能够选择性的诱导神经元分化表型,能够与转化酸性含螺旋蛋白发生相互作用。 | |||
T6761 |
Ossirene
AS101 |
IL Receptor; Caspase; Interleukin | Apoptosis; Immunology/Inflammation; Proteases/Proteasome |
Ossirene (AS101) 是一种免疫调节抑制剂,是一种新型 IL-1beta 转化酶抑制剂,可用于自身免疫性疾病和某些恶性肿瘤。它通过抑制IL-10消除 STAT3 的磷酸化,有效抑制Caspase-1。 | |||
T21919 |
UCF 101
|
Apoptosis | Apoptosis |
UCF 101 是竞争性的促凋亡蛋白酶Omi/HtrA2选择性抑制剂。它对 MI/R 损伤具有明显的心脏保护作用,还具有一定的神经保护作用。它在 543 nm 处具有天然的红色荧光,可用于监视其进入哺乳动物细胞的能力。 | |||
T5403 |
ULK-101
|
Autophagy | Autophagy |
ULK-101 是一种选择性 ULK1抑制剂,可抑制自噬,对 ULK1和 ULK2 的 IC50值分别为 8.3 nM 和 30 nM。 | |||
T14081 |
Enmetazobactam
AAI101 |
Antibacterial | Microbiology/Virology |
Enmetazobactam (AAI101) 是一种广谱β-lactamase 抑制剂,有抗耐药革兰氏阴性细菌。 | |||
T3476 |
JI-101
CGI-1842,JI 101 |
VEGFR; PDGFR; Ephrin Receptor | Angiogenesis; Tyrosine Kinase/Adaptors |
JI-101 (CGI-1842) 是一种有口服活性的多靶点激酶抑制剂,能够抑制VEGFR2,PDGFRβ和EphB4,具有抗癌作用。 | |||
T14989 |
CMPD101
|
ROCK; GRK; PKC | Cell Cycle/Checkpoint; Chromatin/Epigenetic; Cytoskeletal Signaling; GPCR/G Protein; Stem Cells |
CMPD101 是膜透性的 GRK2/3高选择性小分子抑制剂,IC50分别为 18 nM 和 5.4 nM。它针对 GRK1、GRK5 ROCK-2 和 PKCα 的选择性较小,IC50值分别为 3.1 μM,2.3 μM,1.4 μM 和 8.1 μM,可研究心衰疾病。 | |||
T4968 |
KHS 101
|
Microtubule Associated | Cytoskeletal Signaling |
KHS 101 是一种新型转化酸性卷曲螺旋蛋白 3 (TACC3) 的抑制剂。它是神经元分化的选择性诱导剂。 | |||
T4138 |
UCPH-101
UCPH 101 |
transporter | Metabolism |
UCPH-101 是一种兴奋性氨基酸转运子亚型 1 (EAAT1) 的抑制剂(IC50:0.66 μM)。 | |||
T5347 |
CXD101
CXD-101 |
HDAC | Chromatin/Epigenetic; DNA Damage/DNA Repair |
CXD101 是一种选择性和具有口服活性的 I 类HDAC 抑制剂,有抗肿瘤活性,对HDAC1、HDAC2和HDAC3的IC50分别为 63、570 和 550 nM。 | |||
T19062 |
Sulforhodamine 101
磺基罗丹明101,磺基罗丹明 101,SR101 |
Others | Others |
Sulforhodamine 101 (SR101) 是一种两性罗丹明红色荧光染料 (excitation/emission: 586/605 nm),常用于神经元形态的研究,并作为星形胶质细胞的细胞类型选择性荧光标记物,在体内和切片制备中都有应用。 | |||
T2451 |
GlyH-101
GlyH 101 |
CFTR; Autophagy | Autophagy; Membrane transporter/Ion channel |
GlyH-101 是一种可渗透入细胞的 CFTR 阻断剂,Ki 为1.4 uM。 | |||
T13247 |
UK-101
UK101,UK 101 |
Proteasome | Proteases/Proteasome; Ubiquitination |
UK-101 是一种强效且具有选择性的免疫蛋白酶体 LMP2 的抑制剂 ,对 β1i (LMP2) 、 β1c (LMP2) 和 β5 (LMP2) 具有抑制作用,IC50 为 104nM 、15 μM 和 1 μM 。UK-101 对 β1i 的亲和力比β1c 和 β5 亚基分布高的 144 倍和 10 倍。UK-101 可诱导细胞凋亡且可用于研究前列腺癌的相关疾病。 | |||
T8651 |
CAL-101
(S)-2-(1-(9H-Purin-6-ylamino)ethyl)-5-fluoro-3-phenylquinazolin-4(3H)-one,GS-1101,Idelalisib |
PI3K | PI3K/Akt/mTOR signaling |
CAL-101 (Idelalisib) 是 p110δ 的选择性抑制剂(IC50:2.5 nM;在无细胞试验中);显示对 p110δ 的选择性比 p110α/β/γ 高 40 到 300 倍,对 p110δ 的选择性比 C2β、hVPS34、DNA-PK 和 mTOR 高 400 到 4000 倍。 | |||
TP2105L |
UFP-101 acetate
UFP-101 acetate(849024-68-6 free base) |
Opioid Receptor | Endocrinology/Hormones; GPCR/G Protein; Neuroscience |
UFP-101 acetate 是一种特异性和竞争性 NOP 受体拮抗剂 (pKi = 10.24),其特异性是 δ、μ 和 κ 阿片受体的 3000 倍以上。 | |||
T26690 |
AVN-101
|
5-HT Receptor; Adrenergic Receptor; Histamine Receptor | GPCR/G Protein; Immunology/Inflammation; Neuroscience |
AVN-101 是一种非常有效的 5-HT7 受体拮抗剂 (Ki = 153 pM)。 AVN-101 还对组胺 H1 (Ki = 0.58 nM) 和肾上腺素能 α2A、α2B 和 α2C (Ki = 0.41-3.6 nM) 受体表现出相当高的亲和力。 AVN-101在中枢神经系统疾病动物模型中显示出良好的口服生物利用度和促进脑血屏障通透性、低毒性和合理的疗效。 | |||
T13362 |
XY101
|
ROR | Metabolism |
XY101 是一种有效选择性的、代谢稳定的口服 RORγ 反向激动剂,IC50 为 30 nM,Kd 为 380 nM。 | |||
T8550 |
NDMC101
|
Others; NF-κB; Proteasome | NF-κB; Others; Proteases/Proteasome; Ubiquitination |
NDMC101 是有效的破骨细胞形成抑制剂,通过下调 NFATc1 调控基因表达抑制破骨细胞分化。它与 DPP4底物相似,通过抑制DPP4抑制早期 T 细胞激活。它能够用于骨疾病的研究,如类风湿关节炎、滑膜炎等。 | |||
T3108 |
CUDC-101
CUDC 101,CUDC101 |
EGFR; HER; HDAC | Angiogenesis; Chromatin/Epigenetic; DNA Damage/DNA Repair; JAK/STAT signaling; Tyrosine Kinase/Adaptors |
CUDC-101 是一种高效的EGFR、HDAC 和HER2抑制剂,对应的IC50值分别为 2.4、4.4 和 15.7 nM。 | |||
T36935 |
PKUMDL-LC-101-D04
GPX4-Activator-1d4,PKUMDL-LC-101-D04 |
GPX | oxidation-reduction |
PKUMDL-LC-101-D04是一种高效的谷胱甘肽过氧化物酶4(GPX4)的异位激活剂,是一种铁死亡的调节剂。 当在无细胞试验中使用浓度为20 μM 时,GPX4活性增加到对照水平的150%;在野生型而非Gpx4-/-小鼠胚胎成纤维细胞(MEF)提取物中使用浓度为61 μM 时,GPX4活性增加到对照水平的150%。PKUMDL-LC-101-D04(200 μM)能减少胆固醇过氧化氢诱导的MEF 死亡。 | |||
T39347 | RG-101 | ||
RG-101 is a hepatocyte-targeted N-acetylgalactosamine conjugated oligonucleotide that functions as an antagonist for miR-122, an essential host factor in the replication of the hepatitis C virus (HCV). | |||
T68187 |
NIP-101
|
||
NIP-101 is a potent calcium antagonist. | |||
T81294 |
Retrocyclin-101
RC-101 |
||
Retrocyclin-101 是一款具有抗菌和抗病毒特性的肽类化合物。 | |||
T72056 |
KYN-101
|
||
KYN-101是一种高效、选择性的芳香烃受体(AHR)合成拮抗剂,在人HepG2 DRE 荧光素酶报告基因检测中IC50为22 nM,在小鼠Hepa1 Cyp-luc 检测中IC50为23 nM。KYN-101逆转IDO/TDO 介导的肿瘤进展,提高PD-1阻断B16 IDO 荷瘤小鼠和表达内源性高水平IDO 的CT26结直肠癌模型的疗效。 | |||
T70902 |
AQ-101
|
||
AQ-101 is a inhibitor of MDM2, which induces MDM2 protein degradation through a self-ubiquitination and proteasome-mediated mechanism. | |||
T68796 |
Thr101
|
||
Thr101, also known as NOX Inhibitor VII, is a dose-dependent inhibitor of HDAC1, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, and HDAC9. Thr101 is also a NOX inhibitor. | |||
T70144 |
ORP-101
|
||
ORP-101 is a new chemical entity designed with intent to create a large stable molecule and to confer partial μ agonist and full κ-antagonist receptor pharmacology. | |||
T63269 |
Antibacterial agent 101
|
||
Antibacterial agent 101 表现出抗细菌和抗真菌作用(MIC=4-32 μg/mL)。 | |||
T70509 |
INU-101
|
||
INU-101 is an 11β-HSD1 inhibitor. In KKAy mice, ob/ob mice, and ZDF rats, oral administration of INU-101 led to enhanced insulin sensitivity and the lowering of the fasting level of glucose in the blood. INU-101 therefore shows promise as a potential treatment for type 2 diabetes and metabolic syndrome. | |||
T70845 |
FOBISIN101
|
||
FOBISIN101 is a novel inhibitor of all 14-3-3 isoforms in 14-3-3 PPIs. | |||
T75895 |
UFP-101 TFA
|
||
UFP-101 TFA 是一种强效、选择性和竞争性的 NOP 受体拮抗剂,pKi 为 10.24。UFP-101 TFA 对 δ、μ 和 κ 类阿片受体的选择性大于 3000 倍。UFP-101 TFA 具有抗抑郁药样作用。 | |||
T83685 |
UFP101 TFA
|
||
UFP101是一种合成肽类物质,作为nociceptin受体的拮抗剂(Ki为0.06 nM,测试于表达人类受体的CHO细胞中)。它对nociceptin受体的选择性高于κ-opioid受体(Ki为204 nM,测试于表达大鼠受体的CHO细胞中)。UFP101能抑制表达于CHO细胞膜的nociceptin受体释放GTPγS(EC50为1.86 nM)。通过脑室内给药,UFP101(10 nmol/每只动物)能延长小鼠尾巴甩动试验中的尾巴撤回潜伏期。在由盲肠结扎和穿刺诱发的小鼠败血症模型中,UFP101(0.003、0.03及0.3 mg/kg)能提高生存率。 | |||
T83095 | Anticancer agent 101 | ||
Anticanceragent 101,一种丁卡因衍生物,展现出抗癌活性。 | |||
T78871 |
PLM-101
|
||
PLM-101是一种口服抗癌剂,针对FLT3和RET具有选择性抑制作用,有效抑制急性髓系白血病(AML)细胞。通过抑制RET,PLM-101促使FLT3的自噬降解,并且通过抑制PI3K和Ras/ERK信号通路来发挥其抗白血病的活性。在小鼠MV4-11侧翼异种移植模型中,PLM-101以口服剂量3及10 mg/kg显示出抗肿瘤效果,并且在同种异种移植小鼠模型中,剂量为40 mg/kg(口服)亦展现出明显的抗肿瘤功效。 | |||
T67948 |
OY-101
|
||
OY-101为口服生效的特异性P-glycoprotein(P-gp)抑制剂。该化合物可增强耐药性肿瘤的敏感性,并有效逆转多药耐药现象。相较于Tetrandrine,OY-101在水溶性、细胞毒性以及逆转活性方面均表现出改进。 | |||
T69358 |
S101
|
||
S101 is an inhibitor of proliferating T-cells, rescuing mice from superantigen-induced shock. | |||
T81490 |
PHI-101
|
||
PHI-101是口服FLT3抑制剂,在克服多耐药突变方面表现出高效。该化合物对FLT3的ITD或TKD单突变体表现出显著抑制作用,同时也能抑制包括双重(ITD/D835Y或ITD/F691L)和三重(ITD/D835Y/F691L)耐药突变。PHI-101在治疗复发或难治性急性髓系白血病(AML)的研究中显示出应用潜力。 | |||
T69732 | LEI 101 hydrochloride | ||
LEI 101 hydrochloride is potent and selective CB2 partial agonist. | |||
T64692 |
AMY-101 acetate
|
||
Complement component C3 plays a particularly versatile role in this process by keeping the cascade alert, acting as a point of convergence of activation pathways, fueling the amplification of the complement response, exerting direct effector functions, and helping to coordinate downstream immune responses[3]. In C3-/- mice alcohol-induced liver steatosis is absent or strongly reduced after chronic or acute alcohol exposure. This suggests that the complement system and its component C3 contribute... | |||
T36273 |
VH 101 phenol-alkylC4-amine
VH 101 phenol-alkylC4-amine |
||
Functionalized von-Hippel-Lindau protein ligand (VHL) for PROTAC research and development; incorporates an E3 ligase ligand plus an alkylC4 linker with terminal amine ready for conjugation to a target protein ligand. Part of a range of functionalized tool molecules for PROTAC R&D. PROTAC is a registered trademark of Arvinas Operations, Inc., and is used under license. | |||
T71290 |
EVT-101 HCl
|
||
EVT-101 is a GluN2B antagonist, binding at the same GluN1/GluN2B dimer interface as ifenprodil but adopting a remarkably different binding mode involving a distinct subcavity and receptor interactions. | |||
T79249 | Antitumor agent-101 | Histone Methyltransferase | Chromatin/Epigenetic |
Antitumor agent-101是一种针对赖氨酸甲基转移酶G9a/GLP的选择性共价抑制剂,其对G9a的IC50为8.5 nM,对GLP为5.5 nM。在PANC-1异种移植模型中,Antitumor agent-101展现了其抗肿瘤活性。 | |||
T36274 |
VH 101 phenol-alkylC6-amine
VH 101 phenol-alkylC6-amine |
||
Functionalized von-Hippel-Lindau protein ligand (VHL) for PROTAC research and development; incorporates an E3 ligase ligand plus an alkylC6 linker with terminal amine ready for conjugation to a target protein ligand. Part of a range of functionalized tool molecules for PROTAC R&D. PROTAC is a registered trademark of Arvinas Operations, Inc., and is used under license. | |||
T71231 |
VMY-1-101
|
||
VMY-1-101 is a synthesized fluorescent CDK inhibitor. VMY-1-101 demonstrates potent CDK inhibitory activity, enhanced induction of G2/M arrest and modest apoptosis as compared to purvalanol B. | |||
T71593 |
AVN-101 free base
|
||
AVN-101 is a very potent 5-HT7 receptor antagonist, with slightly lesser potency toward 5-HT6, 5-HT2A, and 5HT-2C receptors. It is a multi-target drug candidate for the treatment of CNS disorders. | |||
T68934 | VT101 free base | ||
VT101 is a TEAD Auto-palmitoylation inhibitor that Selectively Inhibit Proliferation and Tumor Growth of NF2-deficient Mesothelioma. VT101 inhibited the firefly luciferase reporter dose-dependently and had no 204 effect on the Renilla luciferase reporter. | |||
T68973 | EVT-101 free base | ||
EVT-101, also known as ENS-101, is an experimental medication which originated from Roche and is under development by Evotec AG for the treatment of major depressive disorder. It acts as a selective NMDA receptor subunit 2B (NR2B) antagonist. | |||
T80521 |
Caveolin-1 (82-101) amide (human, mouse, rat)
Caveolin-1 scaffolding domain peptide |
c-Met/HGFR | Tyrosine Kinase/Adaptors |
Caveolin-1 (82-101) amide (human, mouse, rat) (Caveolin-1 scaffolding domain peptide) 是抑制酪氨酸激酶的肽,可逆转多器官衰老相关的有害变化。 | |||
T26686 |
AV-101
L-4-Cl-KYN,L-4-chlorokynurenine,4-Cl-KYN,4ClKYN,4-Chlorokynurenine,(S)-4-Chlorokynurenine |
NMDAR | Neuroscience |
AV-101 (4-Cl-KYN) 是 NMDA 受体甘氨酸位点的前药拮抗剂,具有抗抑郁活性,可减少 MPTP 猴子中左旋多巴诱导的运动障碍。 |
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T2730 |
Gossypol (acetic acid)
(±)-Gossypol-acetic acid,Pogosin,AT101,醋酸棉酚,乙酸棉子酚,Gossypol acetic acid |
BCL | Apoptosis |
Gossypol acetic acid (AT101) 是一种从棉籽中分离出来的多酚天然产物,分别与 Bcl-xL 蛋白和 Bcl-2蛋白结合,Ki 值分别为 0.5-0.6 μM 和 0.2-0.3 mM。 |